Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002256 · ClinicalTrials.gov registry record · NA
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.
A NA study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
NCT00002256: Completed NA study, sponsored by Hoffmann-La Roche.
NCT00002256 is a NA study that has completed, run by Hoffmann-La Roche. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002256, a NA study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To provide zalcitabine ( ddC ) for patients with AIDS or Advanced ARC in whom zidovudine ( AZT ) is contraindicated, or who have failed treatment with or are intolerant to AZT and to demonstrate that ddC monotherapy is safe, and tolerable in this patient population.
Interventions
- DRUG Zalcitabine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002256 record still lists
NCT00002256 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Zalcitabine is the first listed.
NCT00002256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002256 about?
NCT00002256 is a clinical study titled "Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.". To provide zalcitabine ( ddC ) for patients with AIDS or Advanced ARC in whom zidovudine ( AZT ) is contraindicated, or who have failed treatment with or are intolerant to AZT and to demonstrate that ddC monotherapy is safe, and tolerable in this patient population.
What is the current status of trial NCT00002256?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002256?
The interventions under investigation include: Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00002256?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.